Impact on T-cell depletion and CD34+ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; Comparison with CAMPATH-1M and CAMPATH-1G

Cytotherapy

Volumn 2, Issue 1, 2000, Pages 5-14

  Williams, R J ^a   Clarke, E ^a   Blair, A ^a   Evely, R ^a   Hale, G ^b   Waldmann, H ^b   Brookes, S ^c   Pamphilon, D H ^a  

^a NHS BLOOD AND TRANSPLANT   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

BM; CAMPATH; PBSC; T cell depletion

Indexed keywords

ALEMTUZUMAB; CD3 ANTIGEN; CD34 ANTIGEN; CD52 ANTIGEN; MONOCLONAL ANTIBODY; CAMPATH 1G; CAMPATH 1M; CANCER ANTIBODY; CD19 ANTIGEN; CD56 ANTIGEN; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; TUMOR ANTIGEN;

ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CELL DENSITY; CELL POPULATION; CELL REGENERATION; CYTOLYSIS; DEPLETION; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; KILLER CELL; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; ANIMAL; B LYMPHOCYTE; BONE MARROW CELL; BONE MARROW PURGING; COMPARATIVE STUDY; CYTOLOGY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; LYMPHOCYTE COUNT; METABOLISM; METHODOLOGY; NATURAL KILLER CELL; RAT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, CD; ANTIGENS, CD19; ANTIGENS, CD34; ANTIGENS, CD56; ANTIGENS, NEOPLASM; B-LYMPHOCYTES; BONE MARROW CELLS; BONE MARROW PURGING; GLYCOPROTEINS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTE COUNT; RATS; T-LYMPHOCYTES;

EID: 0034090521     PISSN: 14653249     EISSN: None     Source Type: Journal    
DOI: 10.1080/146532400539008     Document Type: Article

References (25)

1. Waldmann H, Polliak A, Hale G et al. Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1). Lancet 1984;8401:483-6.
2. Hale G, Bright S, Chumbley G et al. Removal of T-cell from BM for transplantation. A monoclonal anti-lymphocyte antibody that fixes human complement. Blood 1983;62:873-82.
3. Hale G, Waldmann H for CAMPATH users. CAMPATH-1 monoclonal antibodies in BM transplantation. J Hematother 1994;3:15-31.
4. Hale G, Cobbold SP, Waldmann H et al. Isolation of low-frequency class-switch variants from rat hybrid myelomas. J Immunol Methods 1987;103:59-67.
5. Riechmann L, Clark M, Waldmann H et al. Reshaping human antibodies for therapy. Nature 1988;332:323-27.
6. Oakhill A, Pamphilon DH, Potter MN et al. Unrelated donor BM transplantation for children with relapsed acute-lymphoblastic leukaemia in second complete remission. Br J Haematol 1996;94:574-8.
7. Hale G, Waldmann H for CAMPATH-1 users. Control of graft-versus-host disease and graft rejection by T-cell depletion of donor and recipient with CAMPATH-1 antibodies. Results of matched sibling transplants for malignant disease. BM Transplant 1994;13:597-611.
8. Franklin IM. A consensus statement on unrelated donor BM transplantation from the consensus Panel chaired by E.C. Gordon-Smith. BM Transplant 1997;19:959.
9. McNiece IK, Langley KE & Zsebo KM. Recombinant human stem cell factor synergises with GM-CSF, G-CSF, IL-3 and Epo to stimulate human progenitor cells of the myeloid and erythroid lineages. Exp Hematol 1991;19:226-31.
10. Kernan NA, Flomberg N, Collins NH et al. Quantitation of T-lymphocytes in human BM by a limiting dilution assay. Transplantation 1985;40:317-22.
11. Hale G, Swirsky D, Waldmann H et al. Reactivity of rat-monoclonal antibody CAMPATH-1 with human leukemic cells and its possible application for autologous BM transplantation. Br J Haematol 1982;60:41-8.
12. Gerritsen EJ, Stam ED, Hermans J et al. Risk factors for developing EBV-related B cell lymphoproliferative disorders (BLPD) after non-HLA-identical BMT in children. BM Transplant 1996;18:377-82.
13. Hale G, Waldmann H for CAMPATH-1 users. Risks of developing EBV-related lymphoproliferative disorders following T cell depleted marrow transplants. Blood 1998;91:3079-83.
14. Curtis RE, Travis LB, Rowlings PA et al. Risk of lymphoproliferative disorders after BM transplantation: A multi-institutional study. Blood 1999;94:2208-16.
15. Schofer O, Veit BC, Johnson FL. Influence of CAMPATH-1 on T- and NK cells. Immun Infekt 1988;16:143-7.
16. Condiotti R, Nagler A CAMPATH-1G impairs natural killer (NK) cell-mediated cytotoxicity. BM Transplant 1996;18:713-20.
17. Barrett AJ Mechanisms of the graft-versus-leukemia reaction. Stem Cells 1997;15:248-58.
18. + selected and CAMPATH-1 treated BM (BM): Evaluation of T cell content and progenitor proliferative potential. Blood 1996;88:254 (abstract).
19. Gilleece MH, Dexter TM Effect of CAMPATH-1H antibody on human hematopoietic progenitors in vitro. Blood 1993;82:807-12.
20. -/lo fetal and adult BM. Immunomethods 1994;5:179-88.
21. Frame JN, Sheehy D, Cartagena C et al. Optimal conditions for in vitro T-cell depletion of human BM by CAMPATH-1 plus complement as demonstrated by limiting dilution analysis. BM Transplant 1989;4:55-61.
22. Jacobs P, Wood L, Fullard L, Waldmann H, Hale G. T-cell depletion by exposure to CAMPATH-1G in vitro prevents graft-versus-host disease. BM Transplant 1993;13:763-9.
23. Hale G, Swirsky DM, Hayhoe FGJ et al. Effects of monoclonal anti-lymphocyte antibodies in vivo in monkeys and humans. Mol Biol Med 1983;1:321-34.
24. Hale G, Clark MR, Marcus R et al. Remission induction in non-Hodgkins's lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet 1988;8625:1394-99.
25. Osterborg A, Fassas AS, Anagnostopoulos A et al. Humanized CD52 monoclonal antibody CAMPATH-1H as first-line treatment in chronic lymphocytic leukaemia. Br J Haematol 1996;93:151-3.